Innovent Biologics, Inc., a global biopharmaceutical company specializing in the development, manufacturing, and commercialization of high-quality medicines across various therapeutic areas, and Sanegene Bio USA Inc. (SanegeneBio), have entered into a strategic collaboration to jointly develop SGB-3908, an siRNA drug candidate designed to target angiotensinogen (AGT) for the treatment of hypertension. In addition to this collaboration, Innovent secures an exclusive option for future licensing rights pertaining to the development, manufacturing, and commercialization of SGB-3908.
SGB-3908, an siRNA drug at the IND-enabling stage, is crafted based on SanegeneBio's proprietary LEAD™ (Ligand and Enhancer Assisted Delivery) platform. The collaboration outlines joint responsibilities for the development of SGB-3908 up to a specified stage. Innovent holds an exclusive option, subject to different exercise fees, to acquire the worldwide development, manufacturing, and commercialization license for SGB-3908. Upon exercising this option, SanegeneBio becomes eligible for milestone payments and tiered royalties based on net sales.
Capitalizing on their respective strengths, SanegeneBio's cutting-edge RNA technology and Innovent's extensive clinical development experience, as well as established commercialization capabilities, will be synergized to accelerate the development and ensure the commercial success of this innovative siRNA drug candidate. The aim is to provide benefits to hypertension patients at the earliest possible stage.
AGT, an upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), plays a crucial role in blood pressure regulation. Inhibiting AGT synthesis, as facilitated by SGB-3908, holds the potential for sustained reductions in AGT protein, leading to decreased angiotensin (Ang) II levels, vasodilation, and ultimately, blood pressure reduction.
Hypertension, affecting over 1 billion people worldwide, poses significant risks of cardiovascular and cerebrovascular diseases, kidney damage, and impaired vision. The partnership aims to address challenges associated with current hypertension treatments, including the need for daily medication and difficulties in perceiving symptoms in milder cases, leading to low compliance. siRNA drugs, offering advantages such as prolonged efficacy, safety, and high compliance, present an alternative solution with the potential to enhance treatment options and provide long-term benefits to patients.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!